909 Davis Street
Evanston, IL 60201
847 871 0377
Full-time employees: 12
|Dr. Andrew D. Kidd B.M. B.Ch., M.D.||Interim Principal Exec. Officer, Principal Financial Officer & Principal Accounting Officer||736.6k||N/A||1976|
|Mr. Craig R. Jalbert CIRA||Pres, Treasurer, Corp. Sec. & Director||N/A||N/A||1962|
|Mr. Patrick Flavin||Sr. Mang. of Corp. Devel. & Investor Relations||N/A||N/A||N/A|
|Ms. Molly Dir||VP of HR||N/A||N/A||N/A|
|Dr. Kathryn King Ph.D.||Sr. VP of Clinical & CMC Operations||N/A||N/A||N/A|
|Mr. Tim Noffke||VP of Program Management & Chief of Staff||N/A||N/A||N/A|
|Dr. Harald Murck M.D., Ph.D.||VP of Clinical & Medical Affairs||N/A||N/A||N/A|
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Aptinyx Inc.’s ISS governance QualityScore as of 1 May 2023 is 10. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 8; Compensation: 10.